Loading
A phase 3 trial of Thermal ablation in Hepatocellular carcinoma, run by Chinese PLA General Hospital, with a status the registry has not verified recently.
Thermal Ablation Combined With Anlotinib and TQB2450 Solution for HCC is a phase 3 interventional study registered as NCT04665609 by Chinese PLA General Hospital, with 80 participants planned, started 2021-03-05 and due to reach its primary completion in 2022-12-31. Interventions recorded: Anlotinib and TQB2450 solution, TQB2450 solution. Conditions recorded: Hepatocellular Carcinoma, Thermal Ablation, Anlotinib, PDL-1.
Linked to the technology Thermal ablation because the registry's title names it ("thermal ablation") and Hepatocellular carcinoma among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Thermal ablation (RFA, microwave, cryo) and the tag pipeline.
Shares Hepatocellular carcinoma and the tag pipeline.
Shares Hepatocellular carcinoma and the tag pipeline.
Shares Hepatocellular carcinoma and the tag pipeline.
Shares Hepatocellular carcinoma and the tag pipeline.
Shares Hepatocellular carcinoma and the tag pipeline.
Shares Hepatocellular carcinoma and the tag pipeline.
Shares Hepatocellular carcinoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/